Search 

Cello Health is organised around three core capabilities - Insight, Consulting and Communications - which allows us to look at complex market challenges through ‘multiple lenses’. This enables us to help healthcare businesses unlock the potential of their assets, brands and organisations in a changing and challenging environment. The formation of Cello Health reflects industry pressure to optimise the potential of molecular assets and demonstrate value, recognises the loss of blockbusters, and the subsequent impact on available resources to bring brands to market. The Cello Health structure gives us a broader view of commercial and clinical success, and enables us to provide a greater depth and breadth of services to help support your critical decision making.

CIMYM BioSciences was established to develop oncology and immunological therapeutics.  At CIMYM we believe passionately that drug development can only be successful if it is patient centred…’Begin with the patient in mind'. As a healthcare company we recognise an exceptional idea to fill a medical need, build a network and then establish a clinical utility that will improve patient care.  CIMYM uses its expertise to manage value-enhancing activities in the development process of pharmaceuticals and diagnostics. It takes a patient-centred approach to co-develop these innovative products and in turn licenses the rights for manufacture and marketing to other pharmaceutical companies.

Crystec applies the latest mSAS (modified supercritical anti-solvent) technologies to improve the design and performance of medicines. We provide crystal and particle engineering solutions to the pharmaceutical and biopharmaceutical industries, contributing to human health by enabling new and more effective therapies. Crystec SCF technologies can be applied to small and large drug molecules in a range of dosage forms. Our services include crystal form screening and particle design (including composite particles and co-crystals), addressing issues of poor solubility and stability, improved delivery, and product enhancement in support of lifecycle management. Our process is scaled to GMP manufacturing levels. We are also engaged in in-house programmes to develop improved products and currently have licensing opportunities available in several therapeutic areas, including urge incontinence, fungal infections, and malaria. The first product based on SCF technology is expected to launch this year. It is an inhaled product for migraine - SCF processing enables exceptional particle size control and lung deposition resulting in rapid uptake. The particle design and scale-up to GMP for this product were managed by members of the Crystec team. Follow us on LinkedIn and Twitter